कंपनी का अवलोकन
Tvardi Therapeutics, Inc. operates as a clinical-stage biopharmaceutical entity focused on the development of novel, oral, and small molecule therapies specifically targeting signal transducer and activator of transcription 3 (STAT3) for the treatment of inflammatory and proliferative diseases. The company functions within the broader Healthcare sector and the specialized Biotechnology industry, positioning itself to address significant unmet medical needs in therapeutic areas where current options are limited. Its current operational scale is reflected in a market capitalization of $28.61M and an employee base consisting of 12 individuals. The combination of a relatively modest market cap and the absence of reported annual revenue indicates that the company is in an early development phase, relying on future product success rather than established commercial sales to drive value.
वित्तीय स्वास्थ्य
The company's financial statements for the trailing twelve months reveal a Net Income of $-18,214,000 and an EBITDA of $-26,653,000, while Revenue is not applicable as the entity has not yet generated commercial sales. The substantial gap between the reported Net Income of $-18,214,000 and the EBITDA figure of $-26,653,000 highlights a significant impact from non-operating expenses or specific accounting treatments that reduce bottom-line profitability below the operating cash earnings level. Free Cash Flow stands at $-15,216,500, which signifies that the company is currently burning cash to fund its research and development activities rather than generating operational liquidity. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a standard characteristic for clinical-stage biotechnology firms that have not yet transitioned to revenue generation. On the balance sheet, the company holds $30.81M in Cash against $201,000 in Debt, resulting in a Debt to Equity ratio of 0.96. Despite the nominal debt figure, the high Debt to Equity ratio of 0.96 suggests a capital structure that requires careful monitoring, though the substantial cash reserve provides a significant buffer against leverage risks. The Current Ratio is 2.86, indicating that the company possesses 2.86 times more current assets than current liabilities, which points to strong short-term liquidity and the ability to meet obligations as they come due. Return on Equity is -237.8% and Return on Assets is -49.7%, metrics that reveal that management effectiveness is currently measured by the consumption of equity and assets to advance the clinical pipeline rather than by generating returns on invested capital.
मूल्यांकन आकलन
Valuation multiples for Tvardi Therapeutics show a P/E Ratio (TTM) of N/A due to negative earnings, while the Forward P/E is listed as -1.17. The negative Forward P/E of -1.17 implies that analysts or market models project the company will continue to operate at a loss in the near term, preventing the establishment of a traditional earnings-based valuation multiple. The Price to Book ratio is 1.37, indicating that the market values the company at 1.37 times its book value, suggesting a slight premium over the net asset value despite the lack of current profitability. The Price to Sales ratio is N/A and the EV/EBITDA is 0.07, metrics that suggest the valuation is heavily dependent on asset backing and cash reserves rather than sales performance or operating earnings. The stock has exhibited significant volatility, trading between a 52-Week High of $43.65 and a 52-Week Low of $2.81. Relative to this wide trading range, the current price sits significantly closer to the lower bound, reflecting the high-risk profile typical of pre-commercial biotechnology assets. The Beta value is N/A, meaning there is insufficient historical data to calculate volatility relative to the broader market, yet the wide range between the high and low prices demonstrates inherent price instability.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, as the company has not yet established a track record of commercial revenue or consistent earnings growth. Without historical revenue data to compare, it is impossible to determine if earnings are growing faster or slower than revenue, as both metrics are currently non-existent in a commercial context. The company does not pay a dividend, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%. This absence of dividend distribution indicates that the company reinvests all available resources, including its $30.81M cash reserve, directly into research, development, and clinical trials rather than distributing income to shareholders. Consequently, the overall growth and income profile is defined entirely by the potential future success of its STAT3-targeting therapies rather than current financial performance or income generation.